当代医药论丛
噹代醫藥論叢
당대의약론총
Contemporary Medicine Forum
2015年
8期
15-16
,共2页
冠心病心力衰竭%美托洛尔%曲美他嗪%心功能
冠心病心力衰竭%美託洛爾%麯美他嗪%心功能
관심병심력쇠갈%미탁락이%곡미타진%심공능
Heart failure in coronary disease%Metoprolol%Trimetazidine%Heart function
目的：探讨联合应用美托洛尔和曲美他嗪治疗冠心病心力衰竭的疗效。方法：对我院收治的106例冠心病心力衰竭患者的临床资料进行回顾性分析，将其分为观察组和对照组，每组各53例患者。为两组患者均进行常规对症治疗，为对照组患者使用曲美他嗪进行治疗，为观察组患者联合应用美托洛尔和曲美他嗪进行治疗，并对比观察两组患者在进行治疗前后心功能、血压、心率的变化。结果：观察组患者在进行治疗后，其LVEF、LVEDD、LVESD及6min步行距离等指标均明显优于对照组患者，差异显著(P＜0.05)，有统计学意义。与进行治疗前相比，两组患者在进行治疗后SBP、DBP及HR的指标较优。与对照组患者相比，观察组患者在进行治疗后SBP、DBP及HR指标的改善幅度更明显，差异显著(P＜0.05)，有统计学意义。结论：联合应用美托洛尔与曲美他嗪治疗冠心病心力衰竭的效果确切，可显著改善患者的心功能、血压及心率，可作为治疗此病的首选用药方案。
目的：探討聯閤應用美託洛爾和麯美他嗪治療冠心病心力衰竭的療效。方法：對我院收治的106例冠心病心力衰竭患者的臨床資料進行迴顧性分析，將其分為觀察組和對照組，每組各53例患者。為兩組患者均進行常規對癥治療，為對照組患者使用麯美他嗪進行治療，為觀察組患者聯閤應用美託洛爾和麯美他嗪進行治療，併對比觀察兩組患者在進行治療前後心功能、血壓、心率的變化。結果：觀察組患者在進行治療後，其LVEF、LVEDD、LVESD及6min步行距離等指標均明顯優于對照組患者，差異顯著(P＜0.05)，有統計學意義。與進行治療前相比，兩組患者在進行治療後SBP、DBP及HR的指標較優。與對照組患者相比，觀察組患者在進行治療後SBP、DBP及HR指標的改善幅度更明顯，差異顯著(P＜0.05)，有統計學意義。結論：聯閤應用美託洛爾與麯美他嗪治療冠心病心力衰竭的效果確切，可顯著改善患者的心功能、血壓及心率，可作為治療此病的首選用藥方案。
목적：탐토연합응용미탁락이화곡미타진치료관심병심력쇠갈적료효。방법：대아원수치적106례관심병심력쇠갈환자적림상자료진행회고성분석，장기분위관찰조화대조조，매조각53례환자。위량조환자균진행상규대증치료，위대조조환자사용곡미타진진행치료，위관찰조환자연합응용미탁락이화곡미타진진행치료，병대비관찰량조환자재진행치료전후심공능、혈압、심솔적변화。결과：관찰조환자재진행치료후，기LVEF、LVEDD、LVESD급6min보행거리등지표균명현우우대조조환자，차이현저(P＜0.05)，유통계학의의。여진행치료전상비，량조환자재진행치료후SBP、DBP급HR적지표교우。여대조조환자상비，관찰조환자재진행치료후SBP、DBP급HR지표적개선폭도경명현，차이현저(P＜0.05)，유통계학의의。결론：연합응용미탁락이여곡미타진치료관심병심력쇠갈적효과학절，가현저개선환자적심공능、혈압급심솔，가작위치료차병적수선용약방안。
Objective: To discuss the effect of Metoprolol and Trimetazidine for heart failure in coronary disease. Methods: 106 patients suffering heart failure in coronary disease were randomly divided into the observation group and the control group, 53 cases in each group. Both groups were treated with traditional methods. The control group was provided the treatment of Trimetazidine. The observation group was provided the treatment of Metoprolol and Trimetazidine. Changes of heart function, blood pressure and heart rate among both groups before and after the treatment were observed. Results: The LVEF, LVEDD, LVESD and 6min walking distance of the observation group patients were obviously better than that of the control group (P<0.05). The blood pressure and heart rate of the observation group patients were obviously better than that of the control group (P<0.05). Conclusion: The Metoprolol and Trimetazidine can effectively treat heart failure in coronary disease and have a bright prospect for application.
